Pharma Business - August 8, 2017
AstraZeneca’s Faslodex receives EU approval
The European Commission (EC) has approved Faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EU approval is based on pivotal data from the Phase III FALCON trial, which demonstrated the superiority of Faslodex 500mg over anastrozole 1mg as a first-line treatment for postmenopausal women with […]
Clinical Trials - May 30, 2016
AZ’s Faslodex met primary endpoint
AstraZeneca announces positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) toArimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer. Faslodex 500mg demonstrated superiority compared with Arimidex 1mg in FALCON, and met its primary […]
